Edison Inv. Res Comments on OpGen, Inc.’s FY2023 Earnings (NASDAQ:OPGN)

OpGen, Inc. (NASDAQ:OPGN – Get Rating) – Investment analysts at Edison Inv. Res issued their FY2023 earnings per share (EPS) estimates for shares of OpGen in a report released on Wednesday, May 17th. Edison Inv. Res analyst A. Aatkar anticipates that the medical research company will post earnings per share of ($3.39) for the year. The consensus estimate for OpGen’s current full-year earnings is ($2.57) per share. Edison Inv. Res also issued estimates for OpGen’s FY2024 earnings at ($2.08) EPS.

Separately, StockNews.com raised shares of OpGen from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th.

OpGen Trading Up 7.9 %

Shares of OpGen stock opened at $0.75 on Monday. The firm has a market capitalization of $4.11 million, a PE ratio of -0.05 and a beta of -0.20. OpGen has a twelve month low of $0.55 and a twelve month high of $16.40. The firm’s 50-day moving average price is $1.08 and its 200 day moving average price is $0.99. The company has a current ratio of 1.24, a quick ratio of 0.88 and a debt-to-equity ratio of 0.58.

OpGen (NASDAQ:OPGN – Get Rating) last announced its quarterly earnings results on Wednesday, March 29th. The medical research company reported ($1.90) earnings per share for the quarter. OpGen had a negative return on equity of 164.45% and a negative net margin of 1,187.02%. The company had revenue of $0.72 million for the quarter.

Institutional Trading of OpGen

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC acquired a new stake in shares of OpGen during the 3rd quarter worth approximately $1,517,000. Vanguard Group Inc. increased its holdings in OpGen by 39.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock valued at $537,000 after purchasing an additional 534,960 shares during the last quarter. HRT Financial LP acquired a new stake in OpGen in the 4th quarter valued at approximately $26,000. Citadel Advisors LLC increased its holdings in OpGen by 571.0% in the 3rd quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 85,754 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in OpGen in the 4th quarter valued at approximately $232,000. Institutional investors and hedge funds own 16.36% of the company’s stock.

About OpGen

(Get Rating)

OpGen, Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It engages in the development of molecular information products and services for global healthcare settings. The firm’s also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms.